Back to today’s briefing

Story perspectives

New Drug Approved for Prostate Cancer, Access Concerns Remain

10/24/2025

46 8 Full Breakdown

Summary

Story summary

The National Institute for Health and Care Excellence (NICE) has approved darolutamide for men with metastatic prostate cancer in England.
It works with androgen deprivation therapy (ADT).
It could benefit about 6,000 patients annually.
Prostate Cancer UK warns of a 'postcode lottery' in access, with under half of men receiving recommended treatments.
Amy Rylance of Prostate Cancer UK says the government must ensure equitable access.

1 of 1

Story summary

The National Institute for Health and Care Excellence (NICE) has approved darolutamide for men with metastatic prostate cancer in England.
It works with androgen deprivation therapy (ADT).
It could benefit about 6,000 patients annually.
Prostate Cancer UK warns of a 'postcode lottery' in access, with under half of men receiving recommended treatments.
Amy Rylance of Prostate Cancer UK says the government must ensure equitable access.